RT Journal Article
SR Electronic
T1 Sarcopenia and Visceral Metastasis at Cabazitaxel Initiation Predict Prognosis in Patients With Castration-resistant Prostate Cancer Receiving Cabazitaxel Chemotherapy
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 1703
OP 1709
DO 10.21873/invivo.12430
VO 35
IS 3
A1 HIROAKI IWAMOTO
A1 HIROSHI KANO
A1 TAKAFUMI SHIMADA
A1 RENATO NAITO
A1 TOMOYUKI MAKINO
A1 SUGURU KADOMOTO
A1 HIROSHI YAEGASHI
A1 KAZUYOSHI SHIGEHARA
A1 KOUJI IZUMI
A1 YOSHIFUMI KADONO
A1 ATSUSHI MIZOKAMI
YR 2021
UL http://iv.iiarjournals.org/content/35/3/1703.abstract
AB Background/Aim: Cabazitaxel is recommended as first-line treatment after docetaxel for metastatic castration-resistant prostate cancer. However, the efficacy, adverse events and prognostic factors associated with cabazitaxel are unclear. Patients and Methods: This single-centre retrospective study including 30 patients with CRPC treated with cabazitaxel between 2014 and 2020 investigated efficacy, outcomes and prognostic factors. Results: Fourteen patients had visceral metastases. The median cabazitaxel dose was 20 mg/m2. The prostate-specific antigen response rate, time to prostate-specific antigen response, and overall survival were 13.3%, 3.48 months, and 7.92 months, respectively. The rates of grade 3 or more neutropenia and febrile neutropenia were 20% and 6.7%, respectively. By multivariate analysis, sarcopenia and visceral metastasis at the time of cabazitaxel initiation were independent and significant factors conferring a poor prognosis. Conclusion: The early introduction of cabazitaxel, prior to the development of sarcopenia and visceral metastasis, might contribute to improved prognosis in CRPC.